ClinicalTrials.gg
RecruitingNCT06684197DEXREMUpdated Oct 23, 2026

The Impact of a Dexmedetomidine Perfusion on Intraoperative Remifentanil Consumption

An interventional study of Dexmedetomidine and Placebo in Dexmedetomidine, Total Intravenous Anesthesia and Remifentanil Consumption, sponsored by Ciusss de L'Est de l'Île de Montréal. Recruiting at 1 site in Canada. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-23.

Sponsored by Ciusss de L'Est de l'Île de Montréal · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started May 2025; still recruiting 1 year 6 months later.
Updated Oct 23, 2026Now RecruitingStart date moved+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
72
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

Opioids analgesic are the gold standard for intraoperative pain management. Their short- and long-term adverse effect motivate anesthesiologists to explore opioid sparing strategies. Dexmedetomidine is a highly selective α2 adrenergic receptor agonist that could help minimize opioid consumption both intraoperative and postoperative due to its sedative, analgesic and sympatholytic properties. This new randomized controlled trial (RCT) will answer the question whether an intraoperative dexmedetomidine infusion compared to placebo has a clinically significant impact on intraoperative remifentanil consumption during a laparoscopic abdominal elective surgery.

Read the detailed description

Opioids analgesic have been used for intraoperative pain management for decades. They are the gold standard for pain relief due to their high efficacy. However, the short- and long-term adverse effects of opioids motivate anesthesia teams to explore opioid sparing strategies employing a combination of analgesics and adjuvants via continuous infusions. Opioid tolerance and opioid-induced hyperalgesia can lead to dose escalation of prescribed opioids and poor pain control.

Dexmedetomidine is a highly selective α2 adrenergic receptor agonist that could help minimize opioid consumption both intraoperative and postoperative due to its sedative, analgesic and sympatholytic properties. Other post-procedure applications such as reduction of cough, agitation and shivering have been described.

Many trials have studied the impact of intraoperative dexmedetomidine on post-operative pain scores, post-operative opioids consumption and common side effects compared with a remifentanil intraoperative infusion. One randomized controlled trial studied the impact of a 30 min dexmedetomidine infusion on intraoperative remifentanil consumption in ASA 1-2 patients undergoing maxillofacial or cervicofacial surgeries. They found a clinically meaningful reduction of 33% of remifentanil consumption at 120 minutes in the dexmedetomidine group. This trial aims to demonstrate a similar reduction when extending to ASA 3 patients undergoing laparoscopic surgery. Furthermore, the investigators aim to evaluate patients' recovery and pain status 24h after the surgery which hasn't been done before in the context of joint dexmedetomidine and remifentanil infusion. The investigators hypothesize that patients of the dexmedetomidine infusion group will require less intraoperative remifentanil to keep the NOL-index into the prespecified range. In the PACU, lower pain score et less opioids requirements are anticipated.

02

Conditions studied

  • Dexmedetomidine
  • Total Intravenous Anesthesia
  • Remifentanil Consumption
  • Remifentanil
  • Laparoscopic Abdominal Surgery
03

In context

Lead sponsor

Ciusss de L'Est de l'Île de Montréal is the lead sponsor of 90 studies on the registry; 32 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ASA 1-3
  • Laparascopic surgery (including general surgery, gynecology, urology) a small abdominal incision (less than 5 cm) will be tolerated.

Exclusion criteria

Exclusion Criteria:

  • Patient refusal
  • Chronic use of opioids
  • Allergy to medication used in the trial
  • Pregnant or breastfeeding women
  • to dexmedetomidine (Bradycardia, arrythmia or pace- maker, severe ventricular dysfunction)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
72 participants (estimated)

Study arms

  • Active comparator
    Dexmedetomidine

    Dexmedetomidine 0.5 mcg/kg (adjusted body weight) ; Administered via infusion pump (Smith Medical Medfusion® 4000 Syringe Infusion Pump) delivered over 10 minutes during induction of general anesthesia, followed by dexmedetomidine 0.5 mcg.kg-1.h-1 (maximum dose: 2.5mcg.kg-1)

    Drug: Dexmedetomidine

  • Placebo comparator
    Placebo - Normal Saline

    Normal saline in volume equivalent of dexmedetomidine dose according to patient weight ; Administered via infusion pump (Smith Medical Medfusion® 4000 Syringe Infusion Pump) so that the full dose is delivered is equivalent to a maximum dose of 2.5mcg.kg-1 of dexemedetomidine

    Drug: Placebo

Interventions

  • Intravenous dexmedetomidine will be given as a bolus (0.5 μg.kg-1) over 10 minutes. A perfusion of 0.5 mcg.kg-1.h-1 of dexmedetomidine will be programmed and maintained up until the pneumoperitoneum is deflated or up until a total dose of 2.5μg.kg-1 has been administered.

  • DrugPlacebo

    Saline will be used instead of dexmedetomidine

06

What researchers measure

Primary outcomes

  1. Remifentanil consumption expressed in mcg.kg-1.h-1

    Compare remifentanil consumption when using an intraoperative dexmedetomidine infusion (bolus of 0.5mcg.kg-1, than infusion of 0.5 mcg.kg-1.h-1, with a maximum dose of 2.5 mcg.kg-1) versus placebo (normal saline)

    Time frame: From induction of anesthesia to end of surgery

Secondary outcomes

  1. Total intraoperative propofol consumption (mg.kg-1.h-1)

    Compare the total intraoperative propofol consumption during anesthesia, to maintien BIS values between 40-60

    Time frame: From induction of anesthesia to end of surgery

  2. Mean intraoperative blood pressure

    Compare intraoperative blood pressure in both groups (mmHg)

    Time frame: From induction of anesthesia to end of surgery

  3. Number of intraoperative episodes of high/low blood pressure

    Compare episodes of high blood pressure (defined as + 20% of patient's baseline) ans episodes of low blood pressure (defined as - 20% of patient's baseline) between both groups

    Time frame: From induction of anesthesia to end of surgery

  4. Number of episodes of intraoperative tachy-/bradycardia

    Compare episodes of tachycardia (defined as \> 100 bpm) and episodes of bradycardia (defined as \< 45 bpm) between both groups

    Time frame: From induction of anesthesia to end of surgery

  5. Total intraoperative dose of vasopressors

    Compare the intraoperative requirements of norepinephrine, ephedrine, glycopyrrolate and atropine.

    Time frame: From induction of anesthesia to end of surgery

  6. intraoperative NOL index

    compare the percentage of time during the intraoperative period for which the NOL index will be above the pain threshold of 25

    Time frame: From intubation to end of surgery

  7. Time for extubation (in minutes)

    Compare the time for extubation

    Time frame: From end of surgery to extubation

  8. Morphine equivalent consumption in the post anesthesia care unit (PACU)

    Compare total amount of morphine equivalent given in the post anesthesia care unit (mesured in mg)

    Time frame: From PACU admission to discharge from PACU (Aldrete Score >=9 / 10)

  9. Pain scores using visual analogue scale (VAS) in PACU

    Compare pain scores using VAS in PACU

    Time frame: From PACU admission to discharge from PACU (Aldrete Score >=9 / 10)

  10. Adverse events in PACU

    Compare adverse events in PACU: hypotension, bradycardia and post-operative nausea and vomiting (PONV)

    Time frame: From PACU admission to discharge from PACU (Aldrete Score >=9 / 10)

  11. Lenght of stay in PACU (in minutes)

    Compare total time for readiness for discharge from PACU between groups assessed by recovery scores (Aldrete's modified score and Maisonneuve-Rosemont PACU score)

    Time frame: From PACU admission to discharge

  12. Pain scores using numeric rating scale (NRS) 24h post-op

    Compare pain score between both groups 24h post-op

    Time frame: post-op day 1

  13. Quality of recovery (QoR) index 24h post-op

    Compare Quality of recovery (QoR) index 24h post-op

    Time frame: post-op day 1

  14. Mean intraoperative heart rate

    Compare intraoperative heart rate in both groups (beats per minute)

    Time frame: From induction of anesthesia to end of surgery

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Coeckelenbergh S, Doria S, Patricio D, Perrin L, Engelman E, Rodriguez A, Di Marco L, Van Obbergh L, Estebe JP, Barvais L, Kapessidou P. Effect of dexmedetomidine on Nociception Level Index-guided remifentanil antinociception: A randomised controlled trial. Eur J Anaesthesiol. 2021 May 1;38(5):524-533. doi: 10.1097/EJA.0000000000001402. PubMed 33259449 ↗
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started May 2025 (actual). Primary completion is estimated for Nov 2026, 18 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 23, 2026: start Nov 2024 → May 2025, primary completion Nov 2025 → Nov 2026 and completion Nov 2025 → Nov 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 8, 2024
First posted
Nov 12, 2024
StartActual
May 9, 2025was Nov 2024
Primary completionEst.
Nov 2026was Nov 2025
CompletionEst.
Nov 2026was Nov 2025
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 23, 2026
Sites
1 site added, 1 site removed
Show site
  • Hôpital Maisonneuve-Rosemont · Montreal, Canada
Show 1 removed
  • Hôpital Maisonneuve-Rosemont · Montréal, Canada
Oct 23, 2026
Start date
Nov 2024→May 9, 2025 (actual)
Oct 23, 2026
Primary completion
Nov 2025→Nov 2026
Oct 23, 2026
Study completion
Nov 2025→Nov 2026
Oct 23, 2026
Show all 1 update
  1. Oct 23, 2026
    Not yet recruiting→Recruiting
    1 site added, 1 site removed
    Show site
    • Hôpital Maisonneuve-Rosemont · Montreal, Canada
    Show 1 removed
    • Hôpital Maisonneuve-Rosemont · Montréal, Canada
    Start date Nov 2024→May 9, 2025 (now actual)
    Primary completion Nov 2025→Nov 2026
    Study completion Nov 2025→Nov 2026
    + 2 other changes: index terms and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06684197
Lead sponsor
Ciusss de L'Est de l'Île de Montréal
Responsible party
Olivier Verdonck (MD, MSc, Clinical Assistant Professor, Head of Department of Anesthesiology and Pain Medecine, Maisonneuve-Rosemont Hospital) — Principal investigator
First posted
Nov 12, 2024
Start date
May 9, 2025
Primary completion
Nov 2026 (estimated)
Completion
Nov 2026 (estimated)
Last update
Oct 23, 2026

Study contacts

Olivier Verdonck
Contact
overdonck@gmail.com
+15142523426
Nadia Godin
Contact
ngodin.hmr@ssss.gouv.qc.ca
+15142523400 ext. 3193

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dexmedetomidine

Start the discussion